Drug profiles
50 medicines with their FDA label, EMA EPAR, approval history, dosing, patents, safety and clinical trials, each linked to its official source.
Cardiovascular
Apixaban (Eliquis)Bristol Myers Squibb 路 Factor Xa inhibitor 路 FDA 2012Rivaroxaban (Xarelto)Bayer 路 Factor Xa inhibitor 路 FDA 2011Sacubitril/Valsartan (Entresto, Neparvis)Novartis 路 Neprilysin inhibitor with an angiotensin II receptor blocker 路 FDA 2015Sotatercept (Winrevair)Merck 路 Activin signaling inhibitor (ActRIIA-Fc fusion protein) 路 FDA 2024
Diabetes and obesity
Dapagliflozin (Farxiga, Forxiga, Edistride)AstraZeneca 路 SGLT2 inhibitor 路 FDA 2014Dulaglutide (Trulicity)Eli Lilly 路 GLP-1 receptor agonist 路 FDA 2014Empagliflozin (Jardiance)Boehringer Ingelheim 路 SGLT2 inhibitor 路 FDA 2014Semaglutide (Ozempic, Rybelsus, Wegovy)Novo Nordisk 路 GLP-1 receptor agonist 路 FDA 2017Tirzepatide (Mounjaro, Zepbound)Eli Lilly 路 Dual GIP and GLP-1 receptor agonist 路 FDA 2022
Hematology
Immunology
Adalimumab (Humira)AbbVie 路 TNF-alpha blocker 路 FDA 2002Dupilumab (Dupixent)Sanofi 路 IL-4 receptor alpha antagonist 路 FDA 2017Guselkumab (Tremfya)Johnson & Johnson 路 IL-23 p19 inhibitor 路 FDA 2017Lanadelumab (Takhzyro)Takeda 路 Plasma kallikrein inhibitor (monoclonal antibody) 路 FDA 2018Risankizumab (Skyrizi)AbbVie 路 IL-23 p19 inhibitor 路 FDA 2019Secukinumab (Cosentyx)Novartis 路 IL-17A inhibitor 路 FDA 2015Upadacitinib (Rinvoq)AbbVie 路 Janus kinase (JAK) inhibitor 路 FDA 2019Ustekinumab (Stelara)Johnson & Johnson 路 IL-12 and IL-23 inhibitor (p40 subunit) 路 FDA 2009
Infectious Disease
Neurology
Apitegromab (Isembyld)Scholar Rock 路 Antibody that blocks myostatin activation (binds promyostatin and latent myostatin) 路 FDA 2026Donanemab (Kisunla)Eli Lilly 路 Antibody against N-truncated pyroglutamate amyloid beta 路 FDA 2024Efgartigimod alfa (Vyvgart)argenx 路 Neonatal Fc receptor (FcRn) blocker 路 FDA 2021Eplontersen (Wainua, Wainzua)AstraZeneca 路 TTR-directed antisense oligonucleotide (GalNAc conjugate) 路 FDA 2023Lecanemab (Leqembi)Eisai 路 Amyloid beta-directed antibody 路 FDA 2023Ocrelizumab (Ocrevus)Roche 路 CD20-directed monoclonal antibody 路 FDA 2017
Oncology
Acalabrutinib (Calquence)AstraZeneca 路 Covalent Bruton's tyrosine kinase (BTK) inhibitor 路 FDA 2017Atezolizumab (Tecentriq)Roche 路 PD-L1 immune checkpoint inhibitor 路 FDA 2016Daratumumab (Darzalex)Johnson & Johnson 路 CD38-directed monoclonal antibody 路 FDA 2015Datopotamab Deruxtecan (Datroway)Daiichi Sankyo 路 Trop-2-directed antibody-drug conjugate 路 FDA 2025Enfortumab Vedotin (Padcev)Astellas and Pfizer 路 Nectin-4-directed antibody-drug conjugate 路 FDA 2019Epcoritamab (Epkinly, Tepkinly)Genmab 路 CD3 x CD20 bispecific T-cell engaging antibody 路 FDA 2023Erdafitinib (Balversa)Johnson & Johnson 路 FGFR kinase inhibitor 路 FDA 2019Ibrutinib (Imbruvica)AbbVie 路 Covalent Bruton's tyrosine kinase (BTK) inhibitor 路 FDA 2013Lenalidomide (Revlimid)Bristol Myers Squibb 路 Thalidomide analogue acting through cereblon 路 FDA 2005Nivolumab (Opdivo)Bristol Myers Squibb 路 PD-1 immune checkpoint inhibitor 路 FDA 2014Osimertinib (Tagrisso)AstraZeneca 路 EGFR tyrosine kinase inhibitor 路 FDA 2015Pembrolizumab (Keytruda)Merck 路 PD-1 immune checkpoint inhibitor 路 FDA 2014Ribociclib (Kisqali)Novartis 路 CDK4/6 inhibitor 路 FDA 2017Trastuzumab Deruxtecan (Enhertu)Daiichi Sankyo 路 HER2-directed antibody-drug conjugate 路 FDA 2019Zidesamtinib (Jideytro)Nuvalent 路 ROS1 tyrosine kinase inhibitor 路 FDA 2026
Ophthalmology
Pain
Psychiatry
Respiratory
Vaccines
Abrysvo (RSVpreF)Pfizer 路 Vaccine against the RSV prefusion F protein (RSVpreF) 路 FDA 2023Comirnaty (BNT162b2)Pfizer and BioNTech 路 mRNA vaccine expressing the SARS-CoV-2 spike (S) antigen 路 FDA 2021Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)Merck 路 Vaccine of L1 virus-like particles from nine HPV types 路 FDA 2014Spikevax (mRNA-1273)Moderna 路 mRNA vaccine expressing the SARS-CoV-2 spike (S) antigen 路 FDA 2022